PTCT
PTC THERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 27 ▲ Jefferies upgrades
- Jul 6 to Jul 14 ▼ 4 days of insider sells: $4.2M by 3 insiders, avg $88.65
- Aug 4 ▼ 1 insider sell $705.7K at $68.57
- Aug 17 to Aug 27 ▼ 5 days of insider sells: $3.8M by 2 insiders, avg $72.26
- Sep 9 to Sep 17 ▼ 4 days of insider sells: $2.7M by 1 insider, avg $67.54
- Sep 9 Trial readout: Results Pending: PTC923 (Phase 3), Completed 50d ago
- Sep 21 ▲ PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AA…
- Sep 30 to Oct 14 ▼ 6 days of insider sells: $1.2M by 3 insiders, avg $64.08
- Oct 12 Trial readout: Results Pending: PTC923 (Phase 3), Completed 83d ago
- Oct 29 ▲ PTC Therapeutics reported Q3 2026 total revenue of $357.6M, well abo…
- Oct 29 ▲ Earnings: PTCT Q3 2026 Earnings: EPS $0.61 (+75.6% vs est)
- Nov 3 ▲ Buyback: PTC Therapeutics Board of Directors Authorizes $500 Millio…
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $12.6M.
- InstitutionsMIXED
Q3 2026: 36 added (2 new), 29 trimmed or exited. Largest new: Squarepoint Ops $18.3M.
- AnalystsBULLISH
18 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −6.3% to 7.78M shares. 7.5 days to cover, ≈9.3% of shares.
- TrendRANGE
5% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| WESTFIELD CAPITAL MANAGEMENT CO LP | ADD | $174.9M |
| UBS Group AG | DOUBLED | $121.8M |
| Pictet Asset Management Holding SA | TRIM | $54.3M |
| MORGAN STANLEY | TRIM | $49.3M |
| Qube Research & Technologies Ltd | DOUBLED | $43.9M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $36.9M |
| BNP Paribas Asset Management Holding S.A. | ADD | $29.1M |
| Invesco Ltd. | TRIM | $27.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +61%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Citigroup MAINTAIN | Buy |
| Oct 30, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 30, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 30, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 8, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Sep 22, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
SCHMERTZLER MICHAEL Director Oct 14, 2026 | SELL | $126.1K |
SCHMERTZLER MICHAEL Director Oct 14, 2026 | SELL | $23.0K |
Boulding Mark Elliott EXEC. VP AND CLO Oct 9, 2026 | EXERCISE | $7.6K |
Boulding Mark Elliott EXEC. VP AND CLO Oct 9, 2026 | SELL | $12.3K |
SCHMERTZLER MICHAEL Director Oct 7, 2026 | SELL | $3.4K |
SCHMERTZLER MICHAEL Director Oct 7, 2026 | SELL | $155.1K |
Boulding Mark Elliott EXEC. VP AND CLO Oct 6, 2026 | EXERCISE | $17.1K |
Boulding Mark Elliott EXEC. VP AND CLO Oct 6, 2026 | SELL | $27.9K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.52 | -$0.01–$1.38 | +279.6% | $313.4M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 2 press releases · 2 bullish · 3 bearish · 1 mixed · 21 neutral- NEUTRAL SC 13GNov 16, 2026
Wellington Management Group LLP disclosed a 6.3% passive stake in PTC Therapeutics via a Schedule 13G, holding 5,287,260 shares as of September 30, 2026. This is a new filing from Wellington (no prior 13G on file), indicating the large asset manager crossed the 5% threshold through its investment…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 16, 2026
CEO Mark Boulding filed a Form 144 notice of intent to sell 2,812 shares of PTC Therapeutics common stock, valued at approximately $177,887, through a broker. The shares were acquired via stock option exercise on the same day.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
RTW Investments, LP disclosed a 1.9% passive stake in PTC Therapeutics via an amended Schedule 13G, holding 1,615,819 shares as of September 30, 2026. This is a new filing from RTW (no prior 13G on file), indicating the healthcare-focused investment firm crossed the 5% threshold through its…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 10, 2026
State Street Corp disclosed a 6.6% passive stake in PTC Therapeutics via a Schedule 13G filed…
A passive 6.6% stake from a large custodian/asset manager is routine and does not signal an activist campaign. Monitor for any future 13D conversion or additional accumulation, but the passive…
All PTCT filing & press-release reports (29)
- SC 13G reportNov 16, 2026
- 144 reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- INST-CLUSTER reportNov 2, 2026
- 8-K reportOct 29, 2026
- INST-CLUSTER reportOct 27, 2026
- CLUSTER reportOct 16, 2026
- 144 reportOct 9, 2026
- 144 reportOct 7, 2026
- 144 reportOct 6, 2026
- PRESS-RELEASE reportSep 21, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportJul 16, 2026
- PRESS-RELEASE reportJul 16, 2026
- CLUSTER reportJul 13, 2026
- CLUSTER reportJul 8, 2026
- CLUSTER reportJun 26, 2026
- 8-K reportJun 16, 2026
- 8-K reportJun 9, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 15, 2026
- 8-K reportApr 28, 2026
- DEFA14A reportApr 20, 2026
- CLUSTER reportApr 1, 2026
- CLUSTER reportMar 5, 2026
- CLUSTER reportMar 5, 2026